PX1 Research provides certified, high-purity Tesamorelin & Ipamorelin blend for sale to academic, biotechnology, and institutional laboratories. Manufactured in USA-based, ISO 17025-accredited facilities, every lot undergoes rigorous analytical testing including RP-HPLC purity verification, mass spectrometry identification, and endotoxin screening for reliable preclinical evaluation.
PX1 Research provides certified, high-purity Tesamorelin & Ipamorelin blend for sale to academic, biotechnology, and institutional laboratories. Manufactured in USA-based, ISO 17025-accredited facilities, every lot undergoes rigorous analytical testing including RP-HPLC purity verification, mass spectrometry identification, and endotoxin screening for reliable preclinical evaluation.
Sourcing a high-purity tesamorelin & ipamorelin blend for sale requires strict analytical verification via reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry (MS). PX1 Research supplies USA-manufactured, highly purified growth hormone secretagogue (GHS) blends formulated specifically for laboratory research, offering lot-specific Certificates of Analysis (COAs), endotoxin compliance testing (<0.01 EU/mg), and verified molecular identity for in vitro and animal model investigations.
When purchasing dual-acting peptide blends for laboratory protocols, researchers must prioritize chemical integrity and stoichiometry. Unverified suppliers often distribute lower-grade reagents with inconsistent peptide ratios or residual manufacturing impurities. PX1 Research enforces stringent quality control across all lyophilized peptide formulations to ensure reproducible experimental data in endocrine, metabolic, and cellular research models.
The combination of Tesamorelin and Ipamorelin represents a dual-pathway approach to modulating somatotropic axis activity in preclinical research models. While individual peptide secretagogues engage single receptor families, combining a GHRH receptor agonist with a selective ghrelin receptor agonist initiates a complementary signaling cascade at the anterior pituitary gland.
Tesamorelin functions as a stabilized synthetic analog of growth hormone-releasing hormone (GHRH), binding specifically to the GHRH receptor (GHRHR) on pituitary somatotropes. This interaction stimulates adenylate cyclase, raising intracellular cyclic adenosine monophosphate (cAMP) and triggering the synthesis and pulsatile exocytosis of endogenous growth hormone (GH). Concurrently, Ipamorelin acts as a selective growth hormone secretagogue receptor (GHS-R1a) agonist, signaling through the phospholipase C (PLC) and inositol trisphosphate (IP3) pathway to mobilize intracellular calcium ions (Ca2+).
Preclinical studies suggest that simultaneous activation of both the cAMP/protein kinase A pathway via GHRHR and the intracellular Ca2+ pathway via GHS-R1a produces an amplified, synergistic secretion of growth hormone. This dual-action mechanism allows researchers to examine maximal somatotrope signaling capacity without exposing target tissues to supraphysiological single-agent concentrations.
Understanding the molecular characteristics of both compounds is critical for designing appropriate solubilization, assay, and storage protocols in the laboratory. Tesamorelin is a 44-amino acid polypeptide modified at the N-terminus with a trans-3-hexenoic acid group. This lipophilic modification increases its enzymatic stability against dipeptidyl peptidase-4 (DPP-IV) degradation relative to native human GHRH(1-44)NH2, extending its functional half-life in aqueous solution and biological matrices.
In contrast, Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2Nal-D-Phe-Lys-NH2. Incorporating non-canonical amino acids—specifically alpha-aminobutyric acid (Aib) and D-configuration residues—confers exceptional stability against plasma endopeptidases and carboxypeptidases. This structural resistance prevents rapid cleavage, allowing sustained receptor occupancy during target binding studies.
When combined into a co-lyophilized formulation, the two peptides maintain distinct physical interaction profiles. Formulations available through our growth hormone secretagogue catalog are co-lyophilized under sterile, inert nitrogen atmosphere conditions to preserve peptide backbone stability and prevent oxidative degradation of sensitive amino acid residues.
A primary focus of growth hormone secretagogue research is achieving robust GH elevation while preserving baseline endocrine specificity. In vitro assays and animal models demonstrate that Ipamorelin exhibits remarkable receptor selectivity for GHS-R1a. Unlike earlier ghrelin mimetics such as GHRP-2 or GHRP-6, preclinical data indicate that Ipamorelin does not induce significant off-target activation of adrenocorticotropic hormone (ACTH), cortisol, or prolactin secretion.
Similarly, preclinical studies on Tesamorelin indicate that its GHRH analog structure selectively targets anterior pituitary GHRH receptors without disturbing thyroid-stimulating hormone (TSH), luteinizing hormone (LH), or adrenal steroid pathways. In vivo rodent models evaluating the blended peptide complex show natural, pulsatile growth hormone release dynamics that mimic endogenous physiological secretagogue patterns rather than continuous, non-physiological GH surges.
Researchers investigating metabolic kinetics, lipolysis models, or tissue-repair pathways frequently utilize this dual blend to evaluate somatotropin-mediated downstream signaling, including insulin-like growth factor 1 (IGF-1) transcription, without confounding variables introduced by elevated glucocorticoid or prolactin signaling.
When evaluating somatotropic research reagents, investigators often compare the Tesamorelin & Ipamorelin blend against individual peptides or alternative secretagogue combinations. The table and comparative notes below highlight key mechanistic distinctions across common growth hormone secretagogues.
For instance, CJC-1295 No DAC serves as a modified GHRH peptide frequently paired with Ipamorelin. However, Tesamorelin features a distinct N-terminal hexenoyl modification that provides a unique pharmacokinetic and receptor binding profile specifically evaluated in metabolic and adipose-tissue preclinical models. Non-peptide oral secretagogues like MK-677 offer sustained GHS-R1a agonism over prolonged durations but lack the precise, controllable pulsatility demonstrated by peptide-based co-formulations.
Researchers seeking detailed mechanistic overviews across all available growth hormone secretagogue classes can explore our comprehensive GH secretagogue research hub for systematic reviews of literature data and receptor binding affinities.
Proper handling and reconstitution protocols are vital to maintain the molecular stability of co-lyophilized peptide blends. Lyophilized cake integrity can be sensitive to mechanical stress, thermal fluctuations, and exposure to light or ambient air. Reconstitution should always be conducted within a certified laminar flow hood using sterile laboratory technique.
For standard in vitro and analytical applications, bacteriostatic water (0.9% benzyl alcohol) or sterile physiological saline (0.9% NaCl) is recommended as the primary diluent. When reconstituting a vial of Tesamorelin 10mg lyophilized powder or dual-blend reagents, inject the solvent slowly down the glass wall of the vial rather than directing the stream directly onto the lyophilized cake. Allow the solvent to gently wet the cake and dissolve passively or with gentle, slow rotation. Never vortex or aggressively shake peptide solutions, as mechanical shear force can induce polypeptide denaturation, aggregation, or precipitation.
Once fully dissolved, inspect the solution under clear lighting. Reference-grade solutions should appear optically clear, colorless, and completely free of visible particulate matter or cloudiness. Any solution exhibiting phase separation or turbidity should be discarded immediately according to institutional laboratory safety guidelines.
Peptides in lyophilized state exhibit superior stability compared to liquid solutions, but long-term preservation requires controlled environmental conditions. Lyophilized vials of the Tesamorelin & Ipamorelin blend should be stored in a dark freezer at -20°C or -80°C upon receipt to prevent thermal hydrolysis and peptide bond cleavage.
Avoid repeated freeze-thaw cycles, as crystal formation during refreezing causes physical shearing of peptide backbones and accelerates aggregation. After reconstitution in a sterile diluent, reconstituted working solutions should be aliquoted into sterile polypropylene microcentrifuge tubes and kept refrigerated at 2°C to 8°C for short-term evaluation (typically up to 14 to 28 days depending on the vehicle) or frozen once at -80°C for extended storage.
Exposure to direct sunlight or ultraviolet light sources must be avoided, as photo-oxidation can target histidine and tryptophan residues within the peptide chain, altering receptor affinity and invalidating quantitative assay results.
Evaluating a supplier for a tesamorelin & ipamorelin blend for sale requires inspecting transparent, lot-specific analytical documentation. High-performance liquid chromatography (RP-HPLC) is the gold standard method used to confirm chemical purity, separating target peptides from truncated sequences or synthesis side-products. Quality standards at PX1 Research require pure peptide single peaks corresponding to >99.0% total purity.
Mass spectrometry (MS) provides absolute verification of molecular weight, confirming that the synthesized peptide mass matches the exact theoretical mass of both Tesamorelin and Ipamorelin without salt adduction or amino acid substitution errors. Institutions purchasing through wholesale research peptide accounts or single-order channels receive access to full spectrum MS data for every batch.
Furthermore, bacterial endotoxin testing via Limulus Amebocyte Lysate (LAL) assay is crucial for cell culture and in vivo animal models. Endotoxins (lipopolysaccharides) can trigger severe inflammatory cytokine cascades in cell lines and laboratory animals, confounding experimental variables. PX1 Research guarantees endotoxin levels below 0.01 EU/mg, verified by independent, ISO 17025-accredited testing laboratories.
PX1 Research is an established USA-based manufacturer and supplier committed to supporting rigorous scientific inquiry. All peptide compounds are synthesized in state-of-the-art, GMP-compliant facilities utilizing automated solid-phase peptide synthesis (SPPS) technology followed by multiple purification passes.
Every batch is assigned a unique lot number linked to its raw material origins and analytical testing profile. Orders ship directly from our secure distribution facilities in California and Arizona, ensuring minimal transit times and heat exposure. Orders placed Monday through Friday before cut-off times ship same-day under protective packaging protocols to preserve physical integrity.
Whether sourcing individual vials of Ipamorelin 5mg vials or bulk quantities of specialized combination blends, institutional buyers can rely on PX1 Research for batch-to-batch consistency, complete transparency, and dedicated customer support for technical specifications.
What is the primary mechanism of a Tesamorelin & Ipamorelin blend in preclinical research?
The blend combines a GHRH receptor agonist (Tesamorelin) and a selective GHS-R1a ghrelin receptor agonist (Ipamorelin). Preclinical studies indicate that activating both signaling pathways simultaneously produces synergistic growth hormone release from pituitary somatotropes.
Does Ipamorelin or Tesamorelin elevate cortisol or prolactin levels in laboratory models?
In vitro and animal models demonstrate high receptor selectivity for both compounds, showing minimal to no significant elevation of off-target hormones such as cortisol, ACTH, or prolactin compared to older secretagogues like GHRP-2 or GHRP-6.
How should a lyophilized Tesamorelin & Ipamorelin vial be stored upon arrival?
Lyophilized vials should be stored at -20°C or -80°C in a dry, dark environment. Reconstituted solutions should be kept refrigerated at 2°C to 8°C and used within a short experimental window to prevent peptide degradation.
What solvent is recommended for reconstituting peptide blends for laboratory use?
Bacteriostatic water (0.9% benzyl alcohol) or sterile physiological saline (0.9% NaCl) are standard diluents for laboratory reconstitution. Swirl or rotate the vial gently; avoid aggressive shaking or vortexing.
How does PX1 Research verify the purity and identity of its peptide blends?
PX1 Research utilizes reverse-phase high-performance liquid chromatography (RP-HPLC) for purity determination (>99%) and mass spectrometry (MS) for precise molecular weight identification, supported by lot-specific COAs from ISO 17025 accredited labs.
What are the endotoxin limits for PX1 Research peptides?
All research peptides supplied by PX1 Research undergo LAL endotoxin testing and are certified to contain <0.01 EU/mg of bacterial endotoxins, making them suitable for sensitive cell culture and animal model applications.
How does Tesamorelin differ structurally from native GHRH?
Tesamorelin is a 44-amino acid peptide featuring a trans-3-hexenoic acid group attached to the N-terminus. This modification enhances stability against enzymatic degradation by dipeptidyl peptidase-4 (DPP-IV).
Can institution laboratories establish bulk or wholesale research accounts with PX1 Research?
Yes, PX1 Research provides dedicated support and tier pricing for academic institutions, biotechnology firms, and commercial laboratories requiring bulk quantities or recurring shipments.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.